PRMT5 and Miyoshi myopathy: The added benefit of PRMT5-inhibition during treatment with melphalan could as such provide evidence to explore whether pre-treatment of MM patients with a PRMT5 inhibitor prior to exposure to melphalan in a transplant setting would have an added benefit in patients with high-risk MM such as del (17p).